Navigation Links
Genesis Technology Group Retains CCG Elite
Date:10/24/2007

LOS ANGELES and LAIYANG, China, Oct. 24 /Xinhua-PRNewswire-FirstCall/ -- Genesis Technology Group Inc. (OTC Bulletin Board: GTEC) (to be known as Genesis Pharmaceutical Enterprises, Inc.) ("GTEC" or "the Company"), a leading pharmaceutical company in the People's Republic of China ("PRC"), today announced that it has retained CCG Elite to design and execute its investor relations campaign.

Genesis, through its wholly-owned subsidiary Laiyang Jiangbo Biotech Technologies Co., Ltd. ("JiangBo"), is engaged in the research, development, manufacture and sale of pharmaceutical products in the PRC. One of the major pharmaceutical companies in the PRC, Genesis offers a full product line of both western medical drugs and Chinese herbal-based medical drugs in tablet, capsule and granule forms. For the year ending June 30, 2007, net sales for Genesis totaled $76.2 million, up approximately 55 percent from $49.2 million in 2006.

"We are a rapidly growing, large non-state-owned pharmaceutical producer in Shandong Province," said Mr. Cao Wubo, the Chairman and CEO of Genesis Technology Group. "We look forward to working with CCG Elite to increase our visibility in both the investment community and with the financial media as we continue to execute our growth strategy."

Pharmaceutical demand in the PRC is forecast to expand by more than 13 percent annually to reach RMB385 billion (about US$51 billion) by 2010. Consumption and production of pharmaceuticals in the PRC is expected to increase rapidly over the long term because of strong economic growth, changing demographic patterns, and the reform and expansion of health care systems.

"JiangBo is a large pharmaceuticals producer with products distributed via hospital and medical outlets in China, with an advanced technology, an experienced management team and a strong, competitive marketing presence," said Crocker Coulson, President of CCG Elite. "The company is well-positioned to take advantage of increasing demand for pharmaceuticals in China. We intend to assist the company to develop a broader following with fund managers and analysts focusing on high growth equities from China through an integrated investor relations program."

The Company maintains a representative office in the United States, where its Chief Financial Officer and a support staff are located. For more information, refer to http://www.Genesis-China.net.

About CCG Elite

CCG Elite is uniquely positioned to provide an outsourced, high-level investor relations solution that combines in-depth understanding of Asia's corporate culture and economic scene with a direct pipeline into the leading funds and broker-dealers in the United States. CCG Elite is a global, full- service investor relations agency with corporate headquarters in Los Angeles, and offices in New York, Newport Beach, Dallas, Hong Kong and Beijing. For further information, contact CCG Elite or visit the company's website at http://www.ccgelite.com.

About Genesis Technology Group, Inc.

Genesis, through its wholly-owned subsidiary Laiyang Jiangbo Biotech Technologies Co., Ltd. ("JiangBo"), is engaged in the research, development, manufacture and sale of pharmaceutical products in the PRC. One of the major pharmaceutical companies in the PRC, Genesis offers a full product line of both western medical drugs and Chinese herbal-based medical drugs in tablet, capsule and granule forms. Jiangbo has several Certificates of Good Manufacturing Practices for Pharmaceutical Products from the Shandong State Drug Administration, and currently produces 5 major product categories in 3 forms.

Safe Harbor Statement

Certain statements set forth in this press release constitute "forward- looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential rights and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

For more information, please contact:

Genesis Technology Group

Ms. Elsa Sung, CFO

Phone: +1-800-867-0078 ext. 602

Email: info@Genesis-China.net

CCG Elite Investor Relations Inc.

Mr. Crocker Coulson, President

Phone: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE Genesis Technology Group Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Genesis of SUPAC
2. Enlarged waistline may predict atherogenesis for postmenopausal women
3. Artificially made protein to inhibit angiogenesis
4. Miracle Baby Boy from a Type 3 osteogenesis imperfecta, Mother
5. Role Of MicroRNAs In Angiogenesis Researched
6. New Angiogenesis Finding May Help Fight Cancer Growth
7. A Combination Of Drugs Used For Anti-Angiogenesis And Apoptosis More Effective
8. Anti-fungal Drug Block Angiogenesis
9. Protein Targets for Carcinogenesis
10. Vedic vibration technology- the new cure for arthritis
11. Biotechnology industry expected to grow into a three billion dollar industry by 2002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
Breaking Medicine Technology: